

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

Evaluation of the effect of Intravenous Desmopressin, Tranexamic Acid, and their combination on intra-operative bleeding during functional endoscopic sinus surgery of adults

Protocol summary

Study aim

Assessing the effect of Intravenous Desmopressin, Tranexamic Acid, and their combination on intra-operative bleeding during functional endoscopic sinus surgery in adults

Design

prospective randomized double-blind clinical trial

Settings and conduct

The study uses double-blind randomization. Participants are assigned to groups using sealed, opaque envelopes, ensuring neither participants nor investigators know the group assignments. This approach aims to reduce bias and improve study reliability.

Participants/Inclusion and exclusion criteria

The study includes adults aged 18-65 undergoing their first bilateral FESS for chronic rhinosinusitis with polyps. Eligible patients must have normal preoperative tests (platelet count, PT, PTT, INR, hemoglobin, BUN, creatinine, sodium, potassium) and be classified as ASA I or II. Excluded are those with Wegener's disease, sarcoidosis, sinonasal cancer, bleeding disorders, allergies to TXA/DDAVP, thromboembolic diseases, seizure history, renal impairment, DIC or other coagulopathies, color vision disorders, pregnant/breastfeeding, heart failure/fluid restriction conditions, hyponatremia/history, revision surgeries, uncontrolled hypertension, significant coronary artery disease or arrhythmias.

Intervention groups

Patients will randomly assign to one of the three study groups: patients in the DDAVP group will receive 0.3 µg/kg of IV DDAVP preoperatively, 15 mg/kg of IV TXA in the TXA group, and 0.3 µg/kg of IV DDAVP + 15 mg/kg of IV TXA in the combination group.

Main outcome variables

Intraoperatively, the duration of surgery (minutes), and total suctioned blood volume (ml), will be recorded. We

are also going to document, the surgical quality field score. Post-operatively any significant adverse effects within 3 days including nausea, vomiting, epistaxis, and headache will be reported

General information

Reason for update

Acronym

TDEFFECT (TXA, DDAVP Efficacy Functional Endoscopic Clinical Trial)

IRCT registration information

IRCT registration number: **IRCT20231112060028N1**

Registration date: **2023-11-15, 1402/08/24**

Registration timing: **registered_while_recruiting**

Last update: **2023-11-15, 1402/08/24**

Update count: **0**

Registration date

2023-11-15, 1402/08/24

Registrant information

Name

Ali Faramarzi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3629 1417

Email address

ali_faramarzi@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-11-12, 1402/08/21

Expected recruitment end date

2024-11-11, 1403/08/21

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of Intravenous Desmopressin, Tranexamic Acid, and their combination on intra-operative bleeding during functional endoscopic sinus surgery of adults

Public title

Intravenous Desmopressin, Tranexamic Acid, and Their Combined Impact on Intra-Operative Bleeding in Functional Endoscopic Sinus Surgery

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

First-time candidates of bilateral FESS due to chronic rhinosinusitis with polyp Patients should have a normal test result (CBC, PT, PTT, renal function tests, electrolytes) Patients classified as American Society of Anesthesiologists (ASA) I and ASA II

Exclusion criteria:

Wegener's disease Sarcoidosis Sinonasal malignancy Bleeding disorders Known hypersensitivity to TXA or DDAVP Active venous or arterial thromboembolic disease History of seizures Renal impairment (defined as a creatinine clearance below 50 mL/min) Disseminated Intravascular Coagulation (DIC) or any coagulopathy Color vision disorders Pregnancy and breastfeeding Heart failure or other conditions needing fluid restrictions Hyponatremia or history of hyponatremia Revision surgeries Poorly controlled hypertension or cerebrovascular disease History of significant coronary artery disease or arrhythmias

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

2

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor

Sample size

Target sample size: **93**

Randomization (investigator's opinion)

Randomized

Randomization description

The randomization method for this double-blinded randomized clinical trial will be conducted using computer-generated random numbers. The assignment of participants to the study groups will be performed in a randomized manner to ensure equal distribution among

the groups. The randomization process will be carried out by an individual who is not directly involved in the recruitment or assessment of participants. Once informed consent is obtained from eligible participants, they will be assigned a unique identification number. The randomization list will be generated using a computer program, which will allocate participants to one of the three study groups: DDAVP group, TXA group, or combination group

Blinding (investigator's opinion)

Double blinded

Blinding description

To ensure the integrity and validity of the study, a double-blind approach will be implemented, where both the participants and the research team will be blinded to the treatment assignments. The blinding method will involve the following measures: 1. Blinded Treatment Allocation: The assignment of participants to the three study groups (DDAVP group, TXA group, and combination group) will be performed using computer-generated random numbers by an independent researcher not involved in the data collection or analysis. The treatment allocation will be concealed from the participants, surgeons, anesthesiologist, and other members of the research team who are directly involved in patient care. 2. Identical Packaging and Labeling: The DDAVP and TXA medications will be prepared and packaged in identical containers with matching labels. The containers will be indistinguishable in appearance, ensuring that neither the participants nor the healthcare providers can differentiate between the treatments. 3. Blinded Administration: The medications (DDAVP and TXA) will be administered intravenously by a nurse or healthcare provider who is not directly involved in the data collection or analysis. The administration will be performed in a separate room away from the surgical area, ensuring that the surgical team remains unaware of the specific treatment being administered. 5. Blinded Data Collection and Analysis: The collection of intraoperative and postoperative data, will be performed by research personnel who are blinded to the treatment assignments. These individuals will not have access to the treatment information during data collection, thereby preventing any potential bias in data recording. 5. Unblinding Procedures: In the case of an emergency or if there is a medical necessity to reveal the treatment assignment for a specific participant, a separate unblinding procedure will be established. This procedure will outline the steps to be followed to maintain the blinding integrity of the study while addressing the participant's needs

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

Street address

Shiraz University of Medical Sciences, Zand St.

City

Shiraz

Province

Fars

Postal code

7134814336

Approval date

2023-11-07, 1402/08/16

Ethics committee reference number

IR.SUMS.MED.REC.1402.360

Health conditions studied

1

Description of health condition studied

Chronic sinusitis

ICD-10 code

J32

ICD-10 code description

Chronic sinusitis

2

Description of health condition studied

Nasal polyp

ICD-10 code

J33

ICD-10 code description

Nasal polyp

Primary outcomes

1

Description

intra-operative blood loss

Timepoint

Intra-operative and at the end of the operation

Method of measurement

The volume of blood suctioned during the operation excluding the normal volume of saline used

2

Description

Surgical field bleeding score

Timepoint

Intraoperative

Method of measurement

BOEZAART grading scale for scoring surgical field bleeding

Secondary outcomes

1

Description

duration of surgery

Timepoint

At the end of the operation

Method of measurement

The end of the operation minus the start of the operation

Intervention groups

1

Description

Intervention group (Desmopressin Group): Patients will undergo general anesthesia and FESS as indicated under the routine standard of care. Patients in the DDAVP group will receive 0.3 µg/kg of IV DDAVP (DESMOPRESSIN INJECTION PARENTERAL 4 µg/1mL, Ferring GmbH, Switzerland), before the start of the operation.

Category

Treatment - Drugs

2

Description

Intervention group (Tranexamic Acid Group): Patients will undergo general anesthesia and FESS as indicated under the routine standard of care. Patients will receive before the operation, 15 mg/kg of IV TXA (TRANEXAMIC ACID INJECTION PARENTERAL 100 mg/1mL 5MILLILITER, Caspian Tamin Pharmaceutical Company, Iran) in the TXA group.

Category

Treatment - Drugs

3

Description

Intervention group (Desmopressin + Tranexamic Acid): Patients will undergo general anesthesia and FESS as indicated under the routine standard of care. Patients in the DDAVP group will receive the combination of 0.3 µg/kg of IV DDAVP (DESMOPRESSIN INJECTION PARENTERAL 4 µg/1mL, Ferring GmbH, Switzerland) and 15 mg/kg of IV TXA (TRANEXAMIC ACID INJECTION PARENTERAL 100 mg/1mL 5MILLILITER, Caspian Tamin Pharmaceutical Company, Iran), before the start of the operation in the combination group.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center**Name of recruitment center**

Dena Hospital

Full name of responsible person

Arash Farbood

Street address

Radfar st.

City

Shiraz

Province

Fars

Postal code

7186764951

Phone

+98 71 3649 0411

Email

info@denahospital.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Mohammad Hashem Hashempur

Street address

Zand st.

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Email

info@sums.ac.ir

Web page address<https://www.sums.ac.ir/>**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

Mohammad Faramarzi, Ali Faramarzi, Arash Farbood

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Persons

Person responsible for general inquiries**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Ali Faramarzi

Position

Research Assistant, Medical student

Latest degree

Medical doctor

Other areas of specialty/work

Ear, Nose, and Throat

Street address

Otolaryngology Research Center, Khalili Teaching Hospital, Khalili St. Shiraz University of Medical Sciences, Shiraz, Iran. Postal code #7134814336

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3629 1417

Fax

+98 71 3629 1417

Email

ali_faramarzi@sums.ac.ir

Web page address<https://scholar.google.com/citations?user=d8gd94cAAAJ&hl=en>**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Arash Farbood

Position

Associate professor

Latest degree

Medical doctor

Other areas of specialty/work

Anesthesiology

Street address

Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3629 1417

Fax

+98 71 3629 1417

Email

farboda@sums.ac.ir

Web page address**Person responsible for updating data****Contact**

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Ali Faramarzi

Position

Research Assistant, Medical student

Latest degree

Medical doctor

Other areas of specialty/work

Ear, Nose, and Throat

Street address

Otolaryngology Research Center, Khalili Teaching Hospital, Khalili St. Shiraz University of Medical Sciences, Shiraz, Iran. Postal code #7134814336

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3629 1417

Fax

+98 71 3629 1417

Email

ali_faramarzi@sums.ac.ir

Web page address

<https://scholar.google.com/citations?user=d8gd94cAAAJ&hl=en>

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

The data that support the findings of this study include study outcomes of the data gathering form.

When the data will become available and for how long

The data will be available from Ali Faramarzi, upon reasonable request for journal peer-reviewers and editors during the publication process and for readers after publication upon reasonable request.

To whom data/document is available

It will be available from Ali Faramarzi, upon reasonable request for journal peer-reviewers and editors during the publication process and for readers after publication upon reasonable request.

Under which criteria data/document could be used

For reviewers of the journal for further review and for other researchers for future studies

From where data/document is obtainable

Ali Faramarzi, MD, Otolaryngology Research Center, Khalili Hospital, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran. Email: ali_faramarzi@sums.ac.ir

What processes are involved for a request to access data/document

Reviewers and editors of the journal to whom the article was submitted. After the publication of the article, other researchers can send their request for access to the data for review by presenting their registered proposal to the plan administrators.

Comments